title: [Plasma endothelin-1 in patients with prostate cancer and its clinical significance].
abstract: OBJECTIVE
  To investigate plasma endothelin-1 (ET-1) level in patients with prostate cancers and its clinical significance.
  
  
  METHODS
  Plasma ET-1 level was measured by radioimmunoassay in 31 patients of prostate cancer (23 with non-HRPC, 8 with HRPC) and 26 patients of BPH.
  
  
  RESULTS
  Compared with each other of the ET-1 level, there were no significant difference among the BPH group,non-HRPC group and HRPC group. No significant difference was found either between bone metastasis (BM) and non- BM, between high and middling differentiation prostate cancer group, as well as in different PSA level groups (P >0.05). But the ET-1 level in low differentiation prostate cancer was notably lower than those of the high and middle respectively (P < 0.05).
  
  
  CONCLUSIONS
  To detect plasma endothelin-1 (ET-1) level is not a useful method to evaluate the development and the prognosis of prostate cancer.
authors: Department of Urology, Changhai Hospital, Shanghai, China.
authors: Wen-quan
authors: WQ
authors: Zhou
authors: Ying-hao
authors: YH
authors: Sun
authors: Chuan-liang
authors: CL
authors: Xu
authors: Jian-ping
authors: JP
authors: Gao
authors: Rui-ji
authors: RJ
authors: Xu